Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1980 2
1982 2
1986 1
1989 1
1991 1
1996 2
1997 1
1998 3
1999 4
2000 4
2001 1
2002 3
2003 2
2005 1
2006 6
2007 2
2009 2
2010 3
2011 2
2012 3
2013 6
2014 7
2015 6
2016 11
2017 14
2018 10
2019 13
2020 11
2021 13
2022 13
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for maximum isaac
Search for Maximus Isaac instead (1 results)
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
Look AHEAD Research Group; Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Look AHEAD Research Group, et al. N Engl J Med. 2013 Jul 11;369(2):145-54. doi: 10.1056/NEJMoa1212914. Epub 2013 Jun 24. N Engl J Med. 2013. PMID: 23796131 Free PMC article. Clinical Trial.
The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for angina during a maximum follow-up of 13.5 years. RESULTS: The trial was stopped early on the basis of a futility analysis when t …
The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization …
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Weber JS, et al. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. Lancet. 2024. PMID: 38246194 Clinical Trial.
Patients with completely resected melanoma (stage IIIB-IV) were assigned 2:1 to receive open-label mRNA-4157 plus pembrolizumab or pembrolizumab monotherapy. mRNA-4157 was administered intramuscularly (maximum nine doses) and pembrolizumab intravenously (maximum 18 …
Patients with completely resected melanoma (stage IIIB-IV) were assigned 2:1 to receive open-label mRNA-4157 plus pembrolizumab or pembroliz …
Effective decoders for DNA codes.
Houghten S, Banik S. Houghten S, et al. Biosystems. 2022 Jan;211:104583. doi: 10.1016/j.biosystems.2021.104583. Epub 2021 Dec 2. Biosystems. 2022. PMID: 34863885
The best accuracy is seen for codes of length 10, for which a maximum accuracy of up to 99.4% is achieved for distance 1 and distance 2 and 3 achieve up to 97.1% and 85.9%, respectively. ...
The best accuracy is seen for codes of length 10, for which a maximum accuracy of up to 99.4% is achieved for distance 1 and distance …
Detecting Orthostatic Intolerance in Long COVID in a Clinic Setting.
Isaac RO, Corrado J, Sivan M. Isaac RO, et al. Int J Environ Res Public Health. 2023 May 12;20(10):5804. doi: 10.3390/ijerph20105804. Int J Environ Res Public Health. 2023. PMID: 37239531 Free PMC article.
Our objectives in this retrospective study were (1) to report on the findings of the NLT; and (2) to compare findings from the NLT with LC symptoms reported on the C19-YRS. METHODS: NLT data, including maximum heart rate increase, blood pressure decrease, number of minutes …
Our objectives in this retrospective study were (1) to report on the findings of the NLT; and (2) to compare findings from the NLT with LC s …
Stereotactic Radiation for Treating Primary and Metastatic Neoplasms of the Spinal Cord.
Liu EK, Silverman JS, Sulman EP. Liu EK, et al. Front Oncol. 2020 Jun 9;10:907. doi: 10.3389/fonc.2020.00907. eCollection 2020. Front Oncol. 2020. PMID: 32582555 Free PMC article. Review.
Further studies are needed to assess the factors that influence the risk of radiation-induced myelopathy when treating spinal cord neoplasms with stereotactic radiation, which can include, but may not be limited to, maximum dose, dose-fractionation, irradiated volume, tumo …
Further studies are needed to assess the factors that influence the risk of radiation-induced myelopathy when treating spinal cord neoplasms …
Ferrofluidic thermal switch in a magnetocaloric device.
Klinar K, Vozel K, Swoboda T, Sojer T, Muñoz Rojo M, Kitanovski A. Klinar K, et al. iScience. 2022 Jan 15;25(2):103779. doi: 10.1016/j.isci.2022.103779. eCollection 2022 Feb 18. iScience. 2022. PMID: 35146394 Free PMC article.
The investigation comprises a parametric analysis of a realistic ferrofluidic thermal switch in terms of the maximum temperature span, cooling power, and coefficient of performance. ...
The investigation comprises a parametric analysis of a realistic ferrofluidic thermal switch in terms of the maximum temperature span …
Antihydrogen accumulation for fundamental symmetry tests.
Ahmadi M, Alves BXR, Baker CJ, Bertsche W, Butler E, Capra A, Carruth C, Cesar CL, Charlton M, Cohen S, Collister R, Eriksson S, Evans A, Evetts N, Fajans J, Friesen T, Fujiwara MC, Gill DR, Gutierrez A, Hangst JS, Hardy WN, Hayden ME, Isaac CA, Ishida A, Johnson MA, Jones SA, Jonsell S, Kurchaninov L, Madsen N, Mathers M, Maxwell D, McKenna JTK, Menary S, Michan JM, Momose T, Munich JJ, Nolan P, Olchanski K, Olin A, Pusa P, Rasmussen CØ, Robicheaux F, Sacramento RL, Sameed M, Sarid E, Silveira DM, Stracka S, Stutter G, So C, Tharp TD, Thompson JE, Thompson RI, van der Werf DP, Wurtele JS. Ahmadi M, et al. Nat Commun. 2017 Sep 25;8(1):681. doi: 10.1038/s41467-017-00760-9. Nat Commun. 2017. PMID: 28947794 Free PMC article.
Here, we describe how an improved synthesis process results in a maximum rate of 10.5 0.6 atoms trapped and detected per cycle, corresponding to more than an order of magnitude improvement over previous work. ...
Here, we describe how an improved synthesis process results in a maximum rate of 10.5 0.6 atoms trapped and detected per cycle, corre …
Radiation-induced inferior brachial plexopathy after stereotactic body radiotherapy: Pooled analyses of risks.
Milano MT, Mavroidis P, Ryckman J, Yorke E, Doucette C, Mahadevan A, Kapitanova I, Spring Kong FM, Marks LB, Grimm J. Milano MT, et al. Radiother Oncol. 2023 May;182:109583. doi: 10.1016/j.radonc.2023.109583. Epub 2023 Feb 25. Radiother Oncol. 2023. PMID: 36842665 Free PMC article.
RESULTS: NTCP models suggest 10% risks associated with brachial plexus maximum dose (D(max)) of 32-34 Gy in 3 fractions and 40-43 Gy in 5 fractions. ...
RESULTS: NTCP models suggest 10% risks associated with brachial plexus maximum dose (D(max)) of 32-34 Gy in 3 fractions and 40-43 Gy …
Left Ventricular Myocardial Dysfunction Evaluation in Thalassemia Patients Using Echocardiographic Radiomic Features and Machine Learning Algorithms.
Taleie H, Hajianfar G, Sabouri M, Parsaee M, Houshmand G, Bitarafan-Rajabi A, Zaidi H, Shiri I. Taleie H, et al. J Digit Imaging. 2023 Dec;36(6):2494-2506. doi: 10.1007/s10278-023-00891-0. Epub 2023 Sep 21. J Digit Imaging. 2023. PMID: 37735309 Free PMC article.
The models were evaluated using various metrics, including the area under the ROC curve (AUC), accuracy (ACC), sensitivity (SEN), and specificity (SPE). Maximum relevance-minimum redundancy-eXtreme gradient boosting (MRMR-XGB) (AUC = 0.73, ACC = 0.73, SPE = 0.73, SEN = 0.7 …
The models were evaluated using various metrics, including the area under the ROC curve (AUC), accuracy (ACC), sensitivity (SEN), and specif …
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Rasco DW, Medina T, Corrie P, Pavlick AC, Middleton MR, Lorigan P, Hebert C, Plummer R, Larkin J, Agarwala SS, Daud AI, Qiu J, Bozon V, Kneissl M, Barry E, Olszanski AJ. Rasco DW, et al. Cancer Chemother Pharmacol. 2023 Jul;92(1):15-28. doi: 10.1007/s00280-023-04544-5. Epub 2023 May 23. Cancer Chemother Pharmacol. 2023. PMID: 37219686 Free PMC article. Clinical Trial.
Primary objectives were to evaluate the safety of tovorafenib administered once every other day (Q2D) or once weekly (QW), and to determine the maximum-tolerated and recommended phase 2 dose (RP2D) on these schedules. ...
Primary objectives were to evaluate the safety of tovorafenib administered once every other day (Q2D) or once weekly (QW), and to determine …
155 results